Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0TZMGC
ADC Name	Trastuzumab-Me-PRX conjugate
Synonyms	Trastuzumab-Me-PRX; FITC-Tras-Me-PRX Click to Show/Hide
Drug Status	Investigative
Indication	In total 2 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	2.2
	3D MOL	2D MOL
Antibody Name	Trastuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Methylated-beta-Cyclodextrin/Pluronic P103-based polyrotaxane (Me-PRX)		Payload Info
Linker Name	Phenyl maleimide PEG2		Linker Info

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	5.5	uM	HeLa cells	Endocervical adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	6.75	uM	Calu-3 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	7.02	uM	SK-OV-3 cells	Ovarian serous cystadenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.50 uM	Negative HER2 expression (HER2-)
Method Description	Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
In Vitro Model	Endocervical adenocarcinoma	HeLa cells		CVCL_0030
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.75 uM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.02 uM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532

References

Ref 1	An antibody-supermolecule conjugate for tumor-specific targeting of tumoricidal methylated -cyclodextrin-threaded polyrotaxanes. J Mater Chem B. 2020 Aug 21;8(31):6975-6987. doi: 10.1039/d0tb00575d. Epub 2020 Jun 23.